Education
About Us
Working with TipRanks
Follow Us
GH Research (GHRS)
NASDAQ:GHRS
GHRS Stock Chart & Stats
$14.10
-$0.22(-2.41%)
At close: 4:00 PM EST
$14.10
-$0.22(-2.41%)
Day’s Range― - ―
52-Week Range$6.72 - $20.50
Previous CloseN/A
Volume14.35K
Average Volume (3M)296.66K
Market Cap
$837.38M
Enterprise Value$465.24M
Total Cash (Recent Filing)$288.51M
Total Debt (Recent Filing)$582.00K
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Feb 26, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding62,028,145
10 Day Avg. Volume274,564
30 Day Avg. Volume296,658
Financial Highlights & Ratios
PEG Ratio-0.91
Price to Book (P/B)2.04
Price to Sales (P/S)0.00
P/FCF Ratio-8.60
Enterprise Value/Market Cap0.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.72K
Enterprise Value/Ebitda-10.93
Forecast
1Y Price Target
$28.60Price Target Upside102.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial StabilityGHRS has a strong cash balance that should provide financial stability into 2027.
Market PotentialGH001 is estimated to be a significant opportunity with potential sales of $1.9 billion in the US by 2035.
Regulatory ProgressEngagement with the FDA remains active, with the investigational new drug (IND) hold narrowed to a single toxicology topic and all other review items resolved.
Bears Say
Competitive PressureCompetitive momentum in short-acting psychedelics combined with the ongoing FDA hold led to a revised $35 price target from $40.
FDA Clinical HoldThe company has been subject to an FDA clinical hold on its investigational new drug for GH001 using a proprietary device.
Safety ConcernsTwo severe adverse events were reported during the OLE Phase 2b study, including one treatment-related event of affect lability and one unrelated event of migraine.
GH Research News
GHRS FAQ
What was GH Research’s price range in the past 12 months?
GH Research lowest stock price was $6.72 and its highest was $20.50 in the past 12 months.
What is GH Research’s market cap?
GH Research’s market cap is $837.38M.
When is GH Research’s upcoming earnings report date?
GH Research’s upcoming earnings report date is Feb 26, 2026 which is in 99 days.
How were GH Research’s earnings last quarter?
GH Research released its earnings results on Nov 06, 2025. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.237 by $0.007.
Is GH Research overvalued?
According to Wall Street analysts GH Research’s price is currently Undervalued.
Does GH Research pay dividends?
GH Research does not currently pay dividends.
What is GH Research’s EPS estimate?
GH Research’s EPS estimate is -0.27.
How many shares outstanding does GH Research have?
GH Research has 62,028,145 shares outstanding.
What happened to GH Research’s price movement after its last earnings report?
GH Research reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.237. Following the earnings report the stock price went down -1.325%.
Which hedge fund is a major shareholder of GH Research?
Currently, no hedge funds are holding shares in GHRS
GH Research Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.60 (102.84% Upside)
$28.60 (102.84% Upside)
Hedge Fund Trend
Decreased
By 193.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.62%
12-Months-Change
Fundamentals
Return on Equity
-17.86%
Trailing 12-Months
Asset Growth
51.43%
Trailing 12-Months
Company Description
GH Research
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
GHRS Stock 12 Month Forecast
Average Price Target
$28.60
▲(102.84% Upside)
Technical Analysis
Relay Therapeutics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Pharming Group
―
Prime Medicine, Inc.
―
Ownership Overview
―
Insiders
4.77% Mutual Funds
58.38% Other Institutional Investors
36.64% Public Companies and
Individual Investors